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to express a bacterial gene used to produce
a human anticoagulant. Cramer infected
tobacco leaf with the bacteria and used it
to grow dozens of transgenic plants pro-
ducing the human blood protein. She is
now extracting the protein and testing it to
see if it has the same qualities as protein
produced by humans. Although it may be
years before any direct medicinal benefit is
derived from tobacco, scientists are pre-
dicting that these new uses may be the sav-
ior of the small tobacco farmer and turn
tobacco from an instrument ofharm to an
instrument ofhealing.
Cyber-schnoz
To find answers to difficult questions, peo-
ple have, for years, been exhorted to follow
their noses. Scientists seeking to under-
stand how environmental toxins affect ani-
mals and people have taken this statement
literally-well, almost. Researchers at the
Chemical Industry Institute ofToxicology
are using an innovative new tool-a com-
puter-generated rat's nose-to study the
effects ofchemicals.
Toxicologists studying rat inhalation
have found that how a chemical toxin
affects an animal, or possibly a person,
depends, in part, on where the chemical
deposits in the respiratory system. Because
inhalation studies are expensive and diffi-
cult because of the numbers of animals
required, researchers began to look for
another way to get the same information,
thus the cyber-schnoz. Kevin Morgan, a
biologist and veterinarian, and Julie
Kimbell, who holds a Ph.D. in differential
geometry, worked for five months at CIIT,
a not-for-profit, industry-funded toxicolo-
gy laboratory, developing a three-dimen-
sional computer model of the inside of a
three-month-old rat's right nostril.
Using the finite elemental method of
solving complex geometrical equations and
more than 600 slides of rat nasal passages,
Morgan and Kimbell devised a model of
the virtual reality nose that allows them to
simulate air carrying environmental toxins
throughout the nasal passages. So far, they
have used the model to examine where
chemicals such as formaldehyde and ozone
deposit in the nasal passages. According to
Morgan, they hope to eventually use the
model to study all types of reactive gases,
vapors, and particles. They hope to be able
to extrapolate this information to tell how
these chemicals may affect the human res-
piratory system.
Morgan and Kimbell use two different
methods to judge the accuracy ofthe infor-
mation generated by the computer nose. In
the first method, they compare the uptake
pattern ofthe distribution offormaldehyde
generated by the computer with actual pat-
terns of nasal lesions in rats exposed to
formaldehyde. In the second method,
photo developer is poured into a laboratory
flow tank containing a geometric pattern
on film which simulates the rat nasal pas-
sages. The rate ofdevelopment ofthe film
creates a pattern that the researchers can
correlate with the computer simulation to
test its validity. Regarding the rate ofcorre-
lation, Morgan said, "We've found it to be
extremely good."
Still, the "technose" has
its limitations. For this rea-
son, Morgan and Kimbell are
working to develop human
and rhesus monkey comput-
er nose models. The human
nose project used magnetic
resonance imaging and CAT
scans to generate the neces-
sary coordinates. According
to Morgan, who is working
primarily on this project,
they are now ready to begin
constructing a model. The
rhesus monkey nose model,
being developed through a
cooperative agreement with
the EPA, is much further
along. Kimbell has begun
the first air flow tests on the
rhesus monkey nose, which
is much larger and much
more similar to a human
nose than the rat's. Said
Morgan, "The monkey is a
good intermediate between
the rat and human." At least
some laboratory rats can now breathe a sigh
ofrelief.
Age-old Genetic Questions
Knowing that tumor incidence increases
with age and that certain gene mutations
are critical events in tumor formation, sci-
entists have long supposed that genetic
mutations leading to cancer increase with
age. Until recently there was no direct evi-
dence ofthis hypothesis, but researchers at
the University ofSouthern California have
now demonstrated that mutations in the
oncogenes responsible for non-Hodgkin's
lymphoma accumulate over the lifetimes of
some individuals, perhaps putting them at
greater risk for developing cancer.
"Age is the single most significant risk
factor for cancer, and the incidence ofmost
cancers rises exponentially with age, said
Gino A. Cortopassi, assistant professor of
molecular pharmacology and toxicology at
the USC School of Pharmacy who led the
experiment, in an article by the Associated
Press. Knowing that the incidence of non-
Hodgkin's lymphoma increases over 40-
fold with age, Cortopassi and colleagues
used a technique called polymerase chain
reaction to examine peripheral blood lym-
phocytes from 53 live patients and 31
autopsies, none of whom had non-Hodg-
kins lymphoma. The team was looking for
translocation mutations in the BCL2 (B-
cell leukemia/lymphoma-2) gene known to
be associated with the disease. The muta-
tions are found in about halfofall cases of
non-Hodgkin's lymphoma.
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Although the researchers 100
found that the frequency of
BCL2 mutations is highly vari-
able among individuals, fre- o-
quencies of mutations in the ,
BCL2 gene were, on average, =
40 times higher in spleens and *0
13 times higher in lympho- g
cytes of people over 61 years i
old compared with the those in
people under 20 years old. , 25
Other studies have shown 0
that changes in expression of
BCL2 prolong the survival of 0
B-cells by delaying pro-
grammed cell death. In the
Cortopassi study, two individ-
uals were tested a second time Hazards of
five months after the initial accountfo
test. They were found to still
have the same translocation mutation, in-
dicating that these cells can persis in the
blood. Cortopassi and colleagues hypothe-
size that people who accumulate a heavy
burden of BCL2 translocations over their
lifetime may be at a higher risk for non-
Hodgkin's lymphoma.
Researchers currently have two
hypotheses as to how the mutations occur
in the BCL2 gene in the first place. In
humans, during normal development of
41-50
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age. The accumulation of mutations in the BCL2 oncoge
rthe increased risk of non-Hodgkin's lymphoma in the elder
the immune system, the DNA of B-lym-
phocytes is rearranged. Sometimes mis-
takes occur during this rearrangement in
which DNA is translocated between the
immunoglobulin gene on chromosome 14
and the BCL2 gene on chromosome 18.
The first hypothesis is that challenges to
the immune system, such as the infections,
over a period of a person's lifetime may
cause proliferation of cells containing pre-
existing BCL2 translocations. Alternatively,
BCL2 translocations might occur
more frequently as a result of
kil: T -exposure to environmental chem-
L - icals or radiation. The longer
- someone lives, the more likely
they are to have such exposures.
In a collaborative study with
Cortopassi, Douglas Bell at the
NIEHS found that the frequency
of BCL2 mutations is significant-
ly increased in the blood ofheavy
smokers, suggesting a link be-
tween BCL2 mutation and expo-
sure. "However," said Bell, "for
0 technical reasons, in these studies
we can't really rule out either of
these two mechanisms."
ne may "It isn't clear why this particu-
rly. lar change is occurring with age,
said Philip Hanawalt, professor
of biology at Stanford University. "The
striking and important thing about the
Cortopassi finding is that this is a known
change in the gene, associated with a par-
ticular type of cancer, and it clearly is
occurring as a function of age in normal
humans that don't have the cancer."
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